arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Imunon, Inc.

IMNN
$0.90 0.00 (+0.07%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Imunon, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.7M
Dividend Yield —
Revenue Growth None
Op. Margin —
ROIC -52.6% ↗
FCF / Share $-0.58 ↗
Trailing P/E —
Price / Book 1.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 4, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$125.00K
— 0.0% —
Net Income Profit after all expenses
$-2.81M
↓ -2.7% —
FCF / Share Free cash flow per share
$-0.58
↑ +75.1% —
Long-Term Debt Long-term obligations
$6.08M
↑ +1.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
2
Cash Quality ↑
65

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 17 years · 67 quarters